Type 2 & other diabetes

Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies

Cardiovasc DiabetolPublished Retrospective cohort study

Authors' conclusion

This study established a strong association between TyG and both ACM and MACEs in patients with T2DM and MASLD in the Wenzhou cohort, with TyG-ACM association independently validated in the NHANES cohort.

Study context

Population
Patients with both T2D and MASLD, Wenzhou Hospital, 2019–2022; supportive NHANES 1999–2018 cohortWenzhou cohort · supportive NHANES 1999-2018 cohort 1,343
Participants
1,021 patients
Exposure
Higher vs lower triglyceride-glucose (TyG) index
Outcome
MACE and all-cause mortality
Follow-up
Median 53.4 months
Methodological detailsparallel supportive analysis in NHANES 1999-2018 cohort
  • Parallel supportive analysis in NHANES 1999-2018 cohort

Main finding

As reported in the abstract

All-cause mortality events

62

MACE events

101

Elevated TyG and all-cause mortality, HR

1.85 (1.25, 2.73) (95% CI)

Elevated TyG and MACE, HR

1.71 (1.26, 2.33) (95% CI)

Observational data: associations, not effects.

Further findings

Subgroups: TyG–MACE association

Association more prominent among individuals below 60

Mediation by estimated glomerular filtration rate (eGFR) and body roundness index (BRI)

eGFR mediated share of TyG effect on all-cause mortality
8.8%
eGFR mediated share of TyG effect on MACE
10.6%
BRI share of TyG effect on all-cause mortality
6.2%

Predictive accuracy

Adding TyG to conventional risk models significantly enhanced predictive accuracy

Original publication

Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies. Cardiovasc Diabetol. Published 18 June 2026. doi:10.1186/s12933-026-03259-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.